Evidence map›Paper›PMID 29056000›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2017

[The progress of studying the mechanisms of immune cells in the regulation of non-alcoholic fatty liver diseases].

Y Bao

Open access · greenAbstract readReview
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Y BaoThe Key Laboratory, the Second Hospital of Jiaxing, Zhejiang 314000, China.
First Hospital of Jiaxing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver diseases (NAFLD) are liver diseases which are strongly associated with obesity. The incidence of NAFLD has been gradually increased in recent years. According to different pathology of the liver, NAFLD include three disease states: simple fatty liver, hepatitis (nonalcoholic steatohepatitis, NASH) and fatty liver cirrhosis. The accumulations of fat around the internal organs, which secrete a wide range of adipokines, such as interleukin-6, contribute the development and progress of NAFLD in obesity. In addition, the liver has been recognized as an immune organ containing several immune cells, for instance, inherited macrophages in the live (kupffer cells), nature killer cells, T lymphocytes, T regulatory cells (Tregs), myeloid-derived suppressor cells (MDSCs), and dendritic cells. These immune cells secret a number of cytokines, such as tumor necrosis factor (TNF-α) and monocyte chemoattractant protein (MCP-1), play important roles in the development of NAFLD. Moreover, a high level of fatty acids in the liver microenvironment, leads to suppress CD4(+)T cells and the loss of CD4(+)T cells in the microenvironment of the liver may be one of key factors which is associated with the progress of NAFLD to cirrhosis and liver cancer. This article aims to review the recent studies in the mechanisms of these immune cells involving in the progress of NAFLD, and to explore the novel strategies targeting these immune cells to control the prevalence of NAFLD and reduce liver fibrosis.

Indexed as

LiverNon-alcoholic Fatty Liver DiseaseCytokinesHepatitisHumansKupffer CellsLiver CirrhosisLiver NeoplasmsMacrophagesObesityCytokinesHepatic stellate cellsImmunity, cellularMechanisms

Identifiers

PMID29056000
PMCPMC12769482
OpenAlexW2967161813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.